Arena Pharmaceuticals Inc
ARNA
ARNA was delisted on the 10th of March, 2022.
215 hedge funds and large institutions have $2.47B invested in Arena Pharmaceuticals Inc in 2019 Q2 according to their latest regulatory filings, with 58 funds opening new positions, 69 increasing their positions, 43 reducing their positions, and 23 closing their positions.
152% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 23
60% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 43
31% more capital invested
Capital invested by funds: $1.88B → $2.47B (+$586M)
19% more call options, than puts
Call options by funds: $19.5M | Put options by funds: $16.4M
17% more funds holding
Funds holding: 184 → 215 (+31)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$50.6M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$23.4M |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$20.9M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$11.2M |
| 5 |
MCM
Matarin Capital Management
New York
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$73.7M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$38.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$16.7M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$16.5M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$11M |
ARNA Hedge Fund Activity: Q2 2019 in Review
215 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q2 2019, worth a combined $2.47B — up 31% from $1.88B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new ARNA positions and 23 closed out — a net gain of 35 holders — while 69 added to existing stakes and 43 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $50.6M. The largest seller was PFM Health Sciences, cutting an estimated $73.7M.
- 215 institutional investors held Arena Pharmaceuticals Inc (ARNA) as of Q2 2019, up from 184 in Q1 2019.
- Funds reported $2.47B of Arena Pharmaceuticals Inc stock for Q2 2019, up 31% quarter-over-quarter.
- 58 funds opened new Arena Pharmaceuticals Inc positions in Q2 2019 and 23 closed out, a net change of +35 holders.
- The largest Arena Pharmaceuticals Inc buyer in Q2 2019 was AllianceBernstein, an estimated $50.6M added.
- The largest Arena Pharmaceuticals Inc seller in Q2 2019 was PFM Health Sciences, an estimated $73.7M sold.
Based on aggregated 13F filings for Q2 2019.